The effect of nanoliposomal formulations on Staphylococcus epidermidis biofilm

Drug Development and Industrial Pharmacy

Volumn 41, Issue 3, 2015, Pages 445-450

  Moghadas Sharif, Niloofar ^a   Fazly Bazzaz, Bibi Sedigheh ^a   Khameneh, Bahman ^a   Malaekeh Nikouei, Bizhan ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bacterial biofilm; Liposomes; Rifampin; Staphylococcus epidermidis; Vancomycin

Indexed keywords

CHLOROFORM; DICETYL PHOSPHATE; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPOSOME; MACROGOL; METHANOL; NANOCAPSULE; OCTADECYLAMINE; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; NANOPARTICLE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; BIOFILM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EVAPORATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NONHUMAN; OPTICAL DENSITY; PARTICLE SIZE; STAPHYLOCOCCUS EPIDERMIDIS; SURFACE CHARGE; SURVIVAL RATE; TIME; ZETA POTENTIAL; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MEDICINAL CHEMISTRY; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; BIOFILMS; CHEMISTRY, PHARMACEUTICAL; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; RIFAMPIN; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 84924959926     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.877483     Document Type: Article

References (34)

1. Monzón M, Oteiza C, Leiva J, et al. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagnostic microbiology and infectious disease. Diagn Microbiol Infect Dis 2002;44:319-24.
2. Mathur T, Singhal S, Khan S, et al. Detection of biofilm formation among the clinical isolates of staphylococci: an evaluation of three different screening methods. Indian J Med Microbiol 2006;24: 25-9.
3. Eftekhar F, Dadaei T. Biofilm formation and detection of icaAB genes in clinical isolates of methicillin resistant Staphylococcus aureus. Iran J Basic Med Sci 2011;14:132-6.
4. Donlan RM. Role of biofilms in antimicrobial resistance. ASAIO J 2000;46:S47.
5. Smith AW. Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev 2005;57:1539-50.
6. Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 2003;5:1213-19.
7. Villain-Guillot P, Gualtieri M, Bastide L, Leonetti JP. In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2007;51:3117-21.
8. Estrela AB, Abraham WR. Combining biofilm-controlling compounds and antibiotics as a promising new way to control biofilm infections. Pharmaceuticals 2010;3:1374-93.
9. Karosi T, Sziklai I, Csomor P. Low-frequency ultrasound for biofilm disruption in chronic rhinosinusitis with nasal polyposis: in vitro pilot study. Laryngoscope 2013;123:17-23.
10. Gagnon RF, Richards GK, Kostiner GB. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv Perit Dial 1994;10:189-92.
11. Cheow WS, Hadinoto K. Lipid-polymer hybrid nanoparticles with rhamnolipid-triggered release capabilities as anti-biofilm drug delivery vehicles. Particuology 2012;10:327-33.
12. Kasimanickam RK, Ranjan A, Asokan GV, et al. Prevention and treatment of biofilms by hybrid-and nanotechnologies. Int J Nanomed 2013;8:2809-19.
13. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997;154:123-40.
14. Alipour M, Suntres ZE, Lafrenie RM, Omri A. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J Antimicrob Chemother 2010;65:684-93.
15. Zhu CT, Xu YQ, Shi J, et al. Liposome combined porous b-TCP scaffold: preparation, characterization, and anti-biofilm activity. Drug Deliv 2010;17:391-98.
16. Kim HJ, Michael Gias EL, Jones MN. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf A Physicochem Eng Asp 1999;149:561-70.
17. Malaekeh-Nikouei B, Jaafari MR, Tabassi SAS, Samiei A. The enhancement of immunosuppressive effects of cyclosporine A on human T-cells using fusogenic liposomes. Colloids Surf B Biointerfaces 2008;67:238-44.
18. Malaekeh-Nikouei B, Davies N. Double loading of cyclosporine A in liposomes using cyclodextrin complexes. PDA J Pharm Sci Technol 2009;63:139-48.
19. Hemanth Kumar A, Chandra I, Geetha R, et al. A validated highperformance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine. Indian J Pharmacol 2004;36:231-3.
20. Vila MMDC, Oliveira RM, Gonçalves MM, Tubino M. Analytical methods for vancomycin determination in biological fluids and in pharmaceuticals. Química Nova 2007;30:395-9.
21. Giandalia G, De Caro V, Cordone L, Giannola LI. Trehalose-hydroxyethylcellulose microspheres containing vancomycin for topical drug delivery. Eur J Pharm Biopharm 2001;52:83-9.
22. Clinical Institute LS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Appproved standard M7-A7; 2006.
23. Pitts B, Hamilton MA, Zelver N, Stewart PS. A microtiter-plate screening method for biofilm disinfection and removal. J Microbiol Methods 2003;54:269-76.
24. Okajima Y, Kobayakawa S, Tsuji A, Tochikubo T. Biofilm formation by Staphylococcus epidermidis on intraocular lens material. Invest Ophthalmol Vis Sci 2006;47:2971-5.
25. Wu WS, Chen CC, Chuang YC, et al. Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillinresistant Staphylococcus aureus. J Microbiol Immunol Infect 2013; 46:89-95.
26. Cerca N, Martins S, Cerca F, et al. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother 2005;56: 331-6.
27. Peck KR, Kim SW, Jung SI, et al. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy 2003;49:189-93.
28. Simon V, Simon M. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters. Scand J Infect Dis Suppl 1990;72:14-19.
29. Sanderson NM, Guo B, Jacob AE, et al. The interaction of cationic liposomes with the skin-associated bacterium Staphylococcus epidermidis: effects of ionic strength and temperature. Biochim Biophys Acta 1996;1283:207-14.
30. Kaszuba M, Robinson AM, Song YH, et al. The visualisation of the targeting of phospholipid liposomes to bacteria. Colloids Surf B Biointerfaces 1997;8:321-32.
31. Jones MN, Song YH, Kaszuba M, Reboiras MD. The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. J Drug Target 1997;5:25-34.
32. Ahmed K, Muiruri PW, Jones GH, et al. The effect of grafted poly (ethylene glycol) on the electrophoretic properties of phospholipid liposomes and their adsorption to bacterial biofilms. Colloids Surf A Physicochem Eng Asp 2001;194:287-96.
33. Jones MN, Kaszuba M, Reboiras MD, et al. The targeting of phospholipid liposomes to bacteria. Biochim Biophys Acta 1994; 119:57-64.
34. Soenen SJH, Brisson AR, De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 2009;30:3691-701.